RANDOLPH, Mass., Sept. 5, 2025 /PRNewswire/ -- This September and October, families, friends, and neighbors across the U.S. and Canada will gather for the Walk & Roll to Cure FSHD. These events unite ...

Sarepta Therapeutics (NASDAQ:SRPT) presented preliminary clinical data from ongoing phase I/II studies of two investigational ...

Facioscapulohumeral muscular dystrophy (FSHD1A, OMIM#158900) is the third most common hereditary muscle disease after Duchenne muscular dystrophy and myotonic dystrophy, with an estimated prevalence ...

An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...

The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

To explore possible mechanisms of pathology in facioscapulohumeral muscular dystrophy (FSHD), we generated a novel library of myogenic cells composed of paired cultures derived from FSHD subjects and ...

Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi. This collaboration ...

Glee's Max Adler recruited a bunch of his fellow TV and Broadway actors to help get the word out for a fundraising event to benefit FSH Muscular Distrophy, a cause very close to his heart Glee star ...

Carlos Romero, right, with Linda Taylor, left, and Noah Linsky, center, who supported Romero when he competed in the ParaClimbing World Championship. Romero, who was diagnosed with facioscapulohumeral ...

The third annual National FSHD Walk & Roll virtual event will take place on Sept. 12. With a goal of finding a cure to facioscapulohumeral muscular dystrophy (FSHD) by 2025, the FSHD Society’s third ...